Skip to main content

Table 1 LY-411575 has no effect on dystrophy size or neurite diameter in APPswe/PS1dE9xYFP mice

From: Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575

Treatment Dystrophy size (μm2) Neurite diameter (μm)
  Control LY-411575 Control LY-411575
Session 1 5.4 ± 0.7 4.7 ± 0.3 0.95 ± 0.04 0.97 ± 0.02
Session 2 4.3 ± 0.9 5.5 ± 0.5 0.95 ± 0.03 1.07 ± 0.05
Session 3 6.3 ± 0.9 6.5 ± 0.5 1.00 ± 0.04 1.12 ± 0.05
Session 4 4.3 ± 0.5 6.2 ± 0.5 0.99 ± 0.05 1.12 ± 0.06
  1. LY-411575 (5 mg/Kg) had no effect on dystrophy size when dystrophies located in close proximity to senile plaques (within 15 μm) were measured in four consecutive imaging sessions using multiphoton imaging. The first imaging session (session 1) was acquired before the commencement of the treatment. Animals received daily gavage administrations of LY-411575 or vehicle for 3 weeks. Imaging was performed on a weekly basis (sessions 2, 3 and 4). Analysis using a two way ANOVA for repeated measures resulted in: sessionXtreatment [F(3,1968) = 1.461; P = 0.223]). Data are from 3–4 mice and 36–534 dystrophies. We also did not detect any significant effect on shaft diameter of the neurites, located within 50 μm of plaques, (two way ANOVA for repeated measures sessionXtreatment [F(3,329) = 0.884; P = 0.450]). Data are from 3–4 mice and 23–111 neurites.